Hinge Health (HNGE) is a publicly traded Digital Therapeutics company founded in 2012 and based in San Francisco, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Hinge Health reported Q3 2026 revenue of $235.0 million, up 52% year-over-year from $154.2 million in Q3 2025. GAAP gross margin was 87% (82% in Q3 2025). GAAP income from operations was $50.3 million (21% operating margin), versus a $6.1 million loss (-4%) a year earlier. GAAP diluted EPS was $0.66 (Q3 2025: -$0.02). Adjusted (non-GAAP) income from operations was $77.2 million, 33% margin. Operating cash flow was $114.6 million and free cash flow was $112.7 million (48% free cash flow margin, per the company). Operationally, the company reported 3,270 clients (up 28% YoY) and LTM calculated billings of $960.3 million (up 54%). It cited growth in MSK, GI and Migraine Care Program client bases and the Cylinder Health acquisition announced in August. Jim Pursley will step down as President effective January 1, 2027 and join the board; Aaryn Pure becomes Chief Commercial Officer. Guidance: Q4 2026 revenue of $249–251 million and adjusted operating income of $81–83 million; full-year 2026 revenue raised to $879–881 million and adjusted operating income raised to $266–268 million (adjusted operating margin midpoint 30%).
Q4 2026 revenue $249–251M; FY2026 revenue raised to $879–881M; FY2026 non-GAAP operating income raised to $266–268M
Simply Wall St estimates Hinge Health may be 20% undervalued as its profitability improves.

Bessemer funds sell Hinge Health shares at prices up to $125.90 on November 11.
Hinge Health CFO James Budge sells $4.37M in stock at prices between $119.52 and $123.34.

A Hinge Health co-founder files a trading plan to sell 200,000 HNGE shares.
Hinge Health shares have risen 188% over one year, with a Simply Wall St analysis judging the stock expensive.
Stifel reiterates a Buy rating and $135 target price on Hinge Health.
Hinge's core program delivers personalized exercise therapy through its app for joint and muscle pain, pelvic floor health, migraine, and balance and mobility. TrueMotion, its patented AI motion-tracking technology, uses the phone camera to give real-time feedback on exercise form. Members also have access to clinicians on Hinge's care team.
Enso is a small wearable device that delivers electrical nerve stimulation for pain relief. It is FDA-cleared for chronic intractable pain and related muscle pain, and Hinge offers it to members as part of its program.
HingeSelect is an in-person musculoskeletal provider network that Hinge launched in 2025. It connects members who need hands-on care with pre-vetted providers, alongside the digital program.
The AI Care Team Assistant is a generative AI tool that drafts messages, pulls together member information and reviews member profiles for Hinge's care team. It automates that work so clinicians can spend more of their time with members.
No recently verified openings are available right now. The company's careers page has the latest.
View all careers ↗